SharonTWilksMD

Oncology • San Antonio, TX

Physician

Join to view full profile

Dr. Wilks is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wilks' full profile

Already have an account?

Office
2130 N.E.Loop 410
Suite #100
San Antonio, TX 78217
Phone+1 210-637-0641

Fax+1 210-656-3687

Education & Training

San Antonio Uniformed Services Health Education ConsortiumResidency, Internal Medicine, 1986 - 1989
UniforMed Services University of the Health Sciences F. Edward Hebert School of MedicineClass of 1986

Certifications & Licensure

TX State Medical License 1998 - 2025
PA State Medical License 1988 - 1998
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Start of enrollment: 2013 May 21
Completed
Phase 2
A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation Start of enrollment: 2012 Aug 01
Completed
Phase 2, Phase 3
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Start of enrollment: 2014 Jan 01
Completed
Phase 1
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

16 citations
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study.
Antoinette R Tan, Gail S Wright, Anu R Thummala, Michael A Danso, Lazar Popovic
Clinical Cancer Research. 2022-02-15
28 citations
Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A r...
Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Lesley Fallowfield, Päivi Auvinen
European Journal of Cancer. 2021-07-01
71 citations
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney, Kevin Kalinsky, Virginia G. Kaklamani, D. R. D'Adamo, Gursel Aktan
Clinical Cancer Research. 2021-06-01

Press Mentions

Texas State Student Diagnosed with Breast Cancer Hopes to Inspire Others with Her JourneyOctober 27th, 2020
Highlights from the San Antonio Breast Cancer SymposiumJanuary 10th, 2020
Cancer Research Making a DifferenceMay 17th, 2018